First Trust Advisors
KALV

First Trust Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

First Trust Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-31,129
Closed -$306K – 2544
2022
Q2 		$306K Sell
31,129
-760
-2% -$8.38K ﹤0.01% 2298
2022
Q1 		$470K Sell
31,889
-1,807
-5% -$26K ﹤0.01% 2272
2021
Q4 		$446K Buy
33,696
+4,166
+14% +$66.3K ﹤0.01% 2313
2021
Q3 		$515K Buy
+29,530
New +$598K ﹤0.01% 2281

Other funds holding KALV

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

First Trust Advisors's KALV Position: Q3 2022 in Review

First Trust Advisors sold out of KalVista Pharmaceuticals (KALV) in Q3 2022, closing a stake of 31,129 shares — an estimated $306K sold.

First Trust Advisors first reported a position in KALV in Q3 2021 and held it in 4 quarters. The position peaked at $515K in Q3 2021. 94 funds tracked by Wall St. Rank hold KALV as of Q3 2022.

  • First Trust Advisors reported no remaining KalVista Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • First Trust Advisors sold 31,129 KalVista Pharmaceuticals shares in Q3 2022, an estimated $306K.
  • First Trust Advisors first reported a position in KalVista Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • First Trust Advisors's KalVista Pharmaceuticals position peaked at $515K in Q3 2021.
  • 94 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2022.

Based on First Trust Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.